
Neurogene Inc. (NGNE) Market Cap
Neurogene Inc. has a market capitalization of $433.7M.
Financials based on reported quarter end 2025-12-31
Price: $27.85
โฒ 2.22 (8.66%)
Market Cap: 433.74M
NASDAQ ยท time unavailable
CEO: Rachel L. McMinn
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2014-03-07
Website: https://www.neurogene.com
Neurogene Inc. (NGNE) - Company Information
Market Cap: 433.74M ยท Sector: Healthcare
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Analyst Sentiment
Based on 8 ratings
Analyst 1Y Forecast: $45.00
Average target (based on 2 sources)
Consensus Price Target
Low
$16
Median
$42
High
$46
Average
$36
Potential Upside: 30.2%
Price & Moving Averages
Related Companies in Healthcare

KEROS THERAPEUTICS INC (KROS)
Healthcare
$0.43B
Mkt Cap

VANDA PHARMACEUTICALS INC (VNDA)
Healthcare
$0.43B
Mkt Cap

COMMUNITY HEALTH SYSTEMS INC (CYH)
Healthcare
$0.44B
Mkt Cap

AQUESTIVE THERAPEUTICS INC (AQST)
Healthcare
$0.43B
Mkt Cap

ROCKET PHARMACEUTICALS INC (RCKT)
Healthcare
$0.42B
Mkt Cap

ESPERION THERAPEUTICS INC (ESPR)
Healthcare
$0.42B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"Headline metrics for the most recent quarter ended 2025-12-31: Revenue reported as 0, net income of -$24.7M, and EPS of -1.60. Net margin is therefore negative, and the company remains loss-making based on the latest figures provided. Free cash flow was also negative at about -$16.8M, with operating cash flow of approximately -$16.7M, while capital expenditures were modest at roughly -$0.1M. On the balance sheet, total assets were about $289.2M versus total liabilities of $24.3M, leaving equity of ~$264.9M. Net debt is reported as -$93.9M, indicating net cash rather than net borrowings. Shareholder returns have been supported by market momentum: the stock is up 32.65% over the past year and 22.98% over the last 6 months, with dividends and buybacks shown as none/absent in this dataset. Valuation specifics (P/E, FCF yield, ROE, and price-based multiples) are not provided, but the fixed analyst target (consensus $45) contrasts with the current price of $21.41. Overall, this profile points to continued operating cash burn despite strong cash positioning and meaningful positive share-price performance."
Revenue Growth
Revenue is reported as 0 for the latest period, providing no measurable growth trend and indicating limited recognized topline activity in the dataset.
Profitability
Net income is -$24.7M and EPS is -1.60, implying negative profitability and no evidence of margin expansion based on the latest figures.
Cash Flow Quality
Free cash flow is negative at about -$16.8M, driven by negative operating cash flow. Capital expenditure is small, but the cash burn remains the key risk. Dividends are $0.
Leverage & Balance Sheet
Balance sheet appears resilient: equity is ~$264.9M and net debt is -$93.9M (net cash). Liabilities are modest relative to assets, supporting near-term flexibility.
Shareholder Returns
Total shareholder return is strongly influenced by capital appreciation: shares are up 32.65% over 1 year and 22.98% over 6 months. Dividends are absent in the dataset, and buybacks are not provided.
Analyst Sentiment & Valuation
Analyst consensus target is $45 versus a current price of $21.41, implying upside in the stated target range. However, key valuation metrics (P/E, FCF yield) are not provided, and profitability is currently negative.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.